EPCAM and neoplasm: Immunoaffinity capture is a marker‐dependent approach that allows to capture EVs with particular antibodies against EV markers, such as the tetraspanins and tumour‐associated markers.117 Exosomal markers include ALG‐2‐inter‐acting protein X (Alix), TSG101, CD63, CD81,44, 45 Flottilin 1,119 FLOT‐1, ICAM, EpCAM, ANXA5,31 SDCBP, CD9,121 and CD82,46, 122 whereas GM130 is an non‐exosomal marker.31 Other techniques include enzyme‐linked immunosorbent assay as well as such conventional protein analyses as mass spectrometry113 and western blotting.117